Literature DB >> 28515251

New Treatment Options for the Management of Multiple Myeloma.

Shaji K Kumar1.   

Abstract

Multiple myeloma (MM) is a complex disease characterized by considerable genetic heterogeneity. The updated NCCN Guidelines for MM have added new "preferred" regimens for transplant and nontransplant candidates, and have moved some formerly "preferred" regimens to the "other" category. Supportive care has improved outcomes for patients, and new treatments in combination have extended survival for patients with MM. Novel agents on the horizon are poised to raise the bar even further.
Copyright © 2017 by the National Comprehensive Cancer Network.

Entities:  

Mesh：

Year:  2017        PMID： 28515251     DOI： 10.6004/jnccn.2017.0080

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  2 in total

1.  Hybrid sequencing-based personal full-length transcriptomic analysis implicates proteostatic stress in metastatic ovarian cancer.

Authors:  Ying Jing; Yi Zhang; Hui Zhu; Ke Zhang; Mei-Chun Cai; Pengfei Ma; Peiye Shen; Zhenfeng Zhang; Minghui Shao; Jing Wang; Minhua Yu; Xia Yin; Meiying Zhang; Yuan Hu; Danni Chen; Wen Di; Xiaojie Wang; Guanglei Zhuang
Journal:  Oncogene       Date:  2019-01-07       Impact factor: 9.867

2.  Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.

Authors:  Paul G Richardson; Fredrik Schjesvold; Katja Weisel; Philippe Moreau; Larry D Anderson; Darrell White; Paula Rodriguez-Otero; Pieter Sonneveld; Monika Engelhardt; Matthew Jenner; Alessandro Corso; Jan Dürig; Michel Pavic; Morten Salomo; Meral Beksac; Albert Oriol; Jindriska Lindsay; Anna Marina Liberati; Monica Galli; Pawel Robak; Alessandra Larocca; Munci Yagci; Filiz Vural; Abraham S Kanate; Ruiyun Jiang; Lara Grote; Teresa Peluso; Meletios Dimopoulos
Journal:  Eur J Haematol       Date:  2021-09-22       Impact factor: 3.674
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.